SCHEMBL21490844

SCHEMBL21490844

Cc1ccc(S(=O)(=O)n2c(C)cc3c(Cl)ccnc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 6/20 0.46
HTT P42858 3/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
HSD11B1 P28845 1/20 0.42
SLC40A1 Q9NP59 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
HSP90AA1 P07900 1/20 0.41
RAB9A P51151 1/20 0.41
ADAM17 P78536 1/20 0.41
KMT2A Q03164 1/20 0.41
KLF5 Q13887 1/20 0.41
COMT P21964 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
PKM P14618 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29959159 0.89 PTGDR2 (0.48) PTGDR2HTTALDH1A1KDM4ESLC40A1
SCHEMBL1154907 0.89 PTGDR2 (0.48) PTGDR2HTTALDH1A1KDM4ESLC40A1
SCHEMBL1749021 0.88 PTGDR2 (0.44) PTGDR2HTTALDH1A1KDM4ENPSR1
SCHEMBL20447706 0.87 TP53 (0.45) PTGDR2L3MBTL1KMT2APOLB
SCHEMBL19643722 0.86 PTGDR2 (0.45) PTGDR2HTTALDH1A1KDM4ENPSR1
SCHEMBL30668847 0.83 PTGDR2 (0.46) PTGDR2HTTALDH1A1KDM4ENPSR1
SCHEMBL13548246 0.83 PTGDR2 (0.46) PTGDR2HTTALDH1A1KDM4ENPSR1
SCHEMBL23911343 0.81 PTGDR2 (0.46) PTGDR2HTTALDH1A1KDM4ENPSR1
SCHEMBL15408335 0.81 LMNA (0.41) PTGDR2HTTALDH1A1KDM4ENPSR1
SCHEMBL1777486 0.80 HSD11B1 (0.41) PTGDR2HTTALDH1A1KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 US disclosed
EP-3555096-B1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2022-11-23 EP disclosed
CN-114685505-A Imidazopyrrolopyridines as JAK family kinase inhibitors 詹森药业有限公司 2022-07-01 CN disclosed
CN-110312719-B Imidazopyrrolopyridines as JAK family kinase inhibitors 詹森药业有限公司 2022-04-15 CN disclosed
US-20210206768-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2021-07-08 US disclosed
US-10981911-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2021-04-20 US disclosed
US-20190322665-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JAK1, JAK2, JAK3 PTGDR2 748/4885HTT 2618/4885ALDH1A1 2835/4885
US-20210206768-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JAK1, JAK2, JAK3 PTGDR2 748/4885HTT 2618/4885ALDH1A1 2835/4885
US-10981911-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JAK1, JAK2, JAK3 PTGDR2 748/4885HTT 2618/4885ALDH1A1 2835/4885
US-20190322665-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JAK1, JAK2, JAK3 PTGDR2 748/4885HTT 2618/4885ALDH1A1 2835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.